Cell-Free Circulating Tumor DNA and Epstein-Barr Virus DNA for Early Diagnosis of Epstein-Barr Virus–Associated Cancers
Menée à Taïwan à partir d'échantillons sanguins prélevés sur 1 720 témoins et 802 patients atteints d'un carcinome rhinopharyngé diagnostiqué entre 2010 et 2014, cette étude évalue la performance et la faisabilité d'une stratégie basée sur la recherche de l'ADN et des anticorps du virus d'Esptein-Barr pour détecter précocement la maladie
Circulating cell-free DNA (cfDNA) is found in plasma.1 In healthy individuals, the major constituent is derived from short-lived nucleated cells, such as polymorphonuclear leukocytes. A smaller fraction comes from long-lived cells, such as lymphocytes,2,3 including memory B cells in our experience. In patients with cancer, DNA from cancer cells is released into plasma as circulating tumor DNA (ctDNA). The presence of somatic mutations detected in plasma cfDNA is increasingly being used to identify the presence of malignancy and to monitor treatment response. This approach has been applied to both solid tumors4 and lymphomas.
Journal of Clinical Oncology , commentaire, 2022